High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: Results of a prospective pilot and phase II study

Annals of Oncology

Volumn 20, Issue 2, 2009, Pages 319-325

  Illerhaus, G ^a   Marks, R ^a   Muller F ^a   Ihorst, G ^a   Feuerhake, F ^a   Deckert, M ^b   Ostertag, C ^a   Finke, Juergen ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

CNS lymphoma; Elderly; Methotrexate; Neurotoxicity; PCNSL

Indexed keywords

DEXAMETHASONE; FOLINIC ACID; LOMUSTINE; METHOTREXATE; PROCARBAZINE; RITUXIMAB;

ACUTE HEART FAILURE; ADULT; AGED; ANEMIA; ANEURYSM RUPTURE; ARTICLE; B CELL LYMPHOMA; BRAIN HEMORRHAGE; CANCER GROWTH; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG WITHDRAWAL; ELDERLY CARE; ENTERITIS; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; HUMAN TISSUE; HYPERTENSION; INFECTION; INTRACRANIAL THROMBOCYTOPENIC BLEEDING; INTRAOCULAR TUMOR; KIDNEY DYSFUNCTION; LEUKOENCEPHALOPATHY; LEUKOPENIA; LIVER DYSFUNCTION; LIVER TOXICITY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE FRACTIONATION; SIDE EFFECT; THROMBOCYTOPENIA; WHOLE BODY RADIATION;

AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIERS ESTIMATE; KARNOFSKY PERFORMANCE STATUS; LEUKOPENIA; LOMUSTINE; LONGITUDINAL STUDIES; LYMPHOMA, NON-HODGKIN; MALE; METHOTREXATE; MIDDLE AGED; PILOT PROJECTS; PROCARBAZINE; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 60549117125     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn628     Document Type: Article

References (36)

1. Nelson DF, Martz KL, Bonner H et al. Non-Hodgkin's lymphoma of the brain: Can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 1992; 23: 9-17.
2. Weller M. Glucocorticoid treatment of primary CNS lymphoma. J Neurooncol 1999; 43: 237-239.
3. Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol 1998; 16: 859-863.
4. Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol 2000; 18: 3144-3150.
5. DeAngelis LM, Seiferheld W, Schold SC et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 2002; 20: 4643-4648.
6. Batchelor T, Carson K, O'Neill A et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: A report of NABTT 96-07. J Clin Oncol 2003; 21: 1044-1049.
7. Pels H, Schmidt-Wolf IG, Glasmacher A et al. Primary central nervous system lymphoma: Results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 2003; 21: 4489-4495.
8. Sandor V, Stark-Vancs V, Pearson D et al. Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol 1998; 16: 3000-3006.
9. Silvani A, Salmaggi A, Eoli M et al. Methotrexate based chemotherapy and deferred radiotherapy for primary central nervous system lymphoma (PCNSL): Single institution experience. J Neurooncol 2006.
10. Gerstner ER, Carson KA, Grossman SA, Batchelor TT. Long-term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiation. Neurology 2008; 70: 401-402.
11. Colombat P, Lemevel A, Bertrand P et al. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: A multicenter phase II study of the GOELAMS group. Bone Marrow Transplant 2006; 38: 417-420.
12. Illerhaus G, Marks R, Ihorst G et al. High-dose chemotherapy with autologous stern-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 2006; 24: 3865-3870.
13. Abrey LE, Ben-Porat L, Panageas KS et al. Primary central nervous system lymphoma: The Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 2006; 24: 5711-5715.
14. Ferreri AJ, Blay JY, Reni M et al. Prognostic scoring system for primary CNS lymphomas: The International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003; 21: 266-272.
15. Filley CM, Kleinschmidt-DeMasters BK. Toxic leukoencephalopathy. N Engl J Med 2001; 345: 425-432.
16. Correa DD, DeAngelis LM, Shi W et al. Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 2004; 62: 548-555.
17. Omuro AM, Ben-Porat LS, Panageas KS et al. Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol 2005; 62: 1595-1600.
18. Abrey LE, Batchelor TT, Ferreri AJM et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005; 23: 5034-5043.
19. DeAngelis LM, Yahalom J, Thaler HT, Kher U. Combined modality therapy for primary CNS lymphoma. J Clin Oncol 1992; 10: 635-643.
20. Freilich RJ, Delattre JY, Monjour A, DeAngelis LM. Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology 1996; 46: 435-439.
21. O'Brien P, Roos D, Pratt G et al. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol 2000; 18: 519-526.
22. Gavrilovic IT, Hormigo A, Yahalom J et al. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 2006; 24: 4570-4574.
23. Herrlinger U, Schabet M, Brugger W et al. German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. Ann Neurol 2002; 51: 247-252.
24. Jahnke K, Korfel A, Martus P et al. High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann Oncol 2005; 16: 445-449.
25. Levin VA, Silver P, Hannigan J et al. Superiority of post-radiotherapy adjuvant, chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 1990; 18: 321-324.
26. Glass J, Gruber ML, Cher L, Hochberg FH. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: Long-term outcome. J Neurosurg 1994; 81: 188-195.
27. Guha-Thakurta N, Damek D, Pollack C, Hochberg FH. Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: Response to therapy and quality of life of patients. J Neurooncol 1999; 43: 259-268.
28. Herrlinger U, Kuker W, Uhl M et al. NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: Final report. Ann Neurol 2005; 57: 843-847.
29. Batchelor T, Grossman S, Carson K, Fisher J. Updated results from NABTT CNS consortium studies in primary CNS lymphoma. Ann Oncol 2005; 16: 125-125.
30. Laack NN, Ballman KV, Brown PB, O'Neill BP. Whole-brain radiotherapy and high-dose methylprednisolone for elderly patients with primary central nervous system lymphoma: Results of North Central Cancer Treatment Group (NCCTG) 96-73-51. Int J Radiat Oncol Biol Phys 2006; 65: 1429-1439.
31. O'Neill BP, Wang CH, O'Fallon JR et al. Primary central nervous system non-Hodgkin's lymphoma (PCNSL): Survival advantages with combined initial therapy? A final report of the North Central Cancer Treatment Group (NCCTG) Study 86-72-52. Int J Radiat Oncol Biol Phys 1999; 43: 559-563.
32. Hoang-Xuan K, Taillandier L, Chinot O et al. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: A multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 2003; 21: 2726-2731.
33. McAllister LD, Doolittle ND, Guastadisegni PE et al. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 2000; 46: 51-60; discussion 60-151.
34. Shah GD, Yahalom J, Correa DD et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 2007; 25: 4730-4735.
35. Panageas KS, Elkin EB, Ben-Porat L et al. Patterns of treatment in older adults with primary central nervous system lymphoma. Cancer 2007; 110: 1338-1344.
36. Ng S, Rosenthal MA, Ashley D, Cher L. High-dose methotrexate for primary CNS lymphoma in the elderly. Neurooncology 2000; 2: 40-44.